CR8783A - Anticuerpos anti-il13 y complejos - Google Patents
Anticuerpos anti-il13 y complejosInfo
- Publication number
- CR8783A CR8783A CR8783A CR8783A CR8783A CR 8783 A CR8783 A CR 8783A CR 8783 A CR8783 A CR 8783A CR 8783 A CR8783 A CR 8783A CR 8783 A CR8783 A CR 8783A
- Authority
- CR
- Costa Rica
- Prior art keywords
- polypeptide
- antibody
- complexes
- antibodies
- crystals
- Prior art date
Links
- 239000013078 crystal Substances 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Otolaryngology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Se describen anticuerpos anti-IL-13, cristales de anticuerpos anti-IL-13, complejos polipeptido IL- 13/anticuerpo anti-IL-13, cristales de complejos polipeptido IL-13/anticuerpo anti-IL-13, complejos polipeptido IL- 13Ral/polipeptido IL-13/anticuerpo anti-IL-13, cristales de complejos polipeptido IL-13Ral/polipeptido IL-13/anticuerpo anti-IL-13, y metodos y sistemas de software relacionados.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57873604P | 2004-06-09 | 2004-06-09 | |
US57847304P | 2004-06-09 | 2004-06-09 | |
US58137504P | 2004-06-22 | 2004-06-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR8783A true CR8783A (es) | 2007-06-08 |
Family
ID=35503715
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR8784A CR8784A (es) | 2004-06-09 | 2006-12-05 | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
CR8783A CR8783A (es) | 2004-06-09 | 2006-12-05 | Anticuerpos anti-il13 y complejos |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR8784A CR8784A (es) | 2004-06-09 | 2006-12-05 | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
Country Status (19)
Country | Link |
---|---|
US (2) | US7615213B2 (es) |
EP (3) | EP1756161A2 (es) |
JP (4) | JP2008515776A (es) |
KR (3) | KR101462878B1 (es) |
CN (2) | CN101141980B (es) |
AR (2) | AR049390A1 (es) |
AU (2) | AU2005253981B2 (es) |
BR (2) | BRPI0510881A (es) |
CA (2) | CA2567129A1 (es) |
CR (2) | CR8784A (es) |
EC (2) | ECSP067072A (es) |
IL (2) | IL179093A0 (es) |
MX (2) | MXPA06014298A (es) |
NO (2) | NO20070087L (es) |
NZ (1) | NZ582046A (es) |
RU (2) | RU2427589C2 (es) |
SG (2) | SG135207A1 (es) |
TW (1) | TWI391133B (es) |
WO (2) | WO2005123126A2 (es) |
Families Citing this family (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7883704B2 (en) | 1999-03-25 | 2011-02-08 | Abbott Gmbh & Co. Kg | Methods for inhibiting the activity of the P40 subunit of human IL-12 |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
EP1444989A1 (en) * | 2003-02-07 | 2004-08-11 | Giorgio Dr. Stassi | Sensitizing cells for apoptosis by selectively blocking cytokines |
PT1703893E (pt) | 2003-12-23 | 2012-06-01 | Genentech Inc | Novos anticorpos anti-il 13 e as respectivas utilizações |
US7501121B2 (en) * | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
US20090098142A1 (en) * | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
TWI307630B (en) * | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
JP2008520684A (ja) * | 2004-11-17 | 2008-06-19 | アブジェニックス・インコーポレーテッド | Il−13に対する完全ヒトモノクローナル抗体 |
KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
EP1877074B1 (en) | 2005-04-15 | 2013-03-27 | The Government of the United States of America, as represented by the Secretary of Health and Human Services | Treatment and prevention of inflammatory bowel disease involving il-13 and nkt cells |
AU2006296399B2 (en) | 2005-09-30 | 2011-01-20 | Medimmune Limited | Interleukin-13 antibody composition |
US20070202106A1 (en) * | 2005-10-06 | 2007-08-30 | Baylor Research Institute | Compositions and methods for the treatment of cancer |
US20070237763A1 (en) * | 2005-10-06 | 2007-10-11 | Baylor Research Institute | Compositions and methods for the treatment of cancer |
KR20080049113A (ko) * | 2005-10-21 | 2008-06-03 | 노파르티스 아게 | Il-13에 대항한 인간 항체 및 치료적 용도 |
CN102898519B (zh) | 2005-11-30 | 2015-10-28 | Abbvie公司 | 抗淀粉样β蛋白的单克隆抗体及其用途 |
AU2006330858A1 (en) * | 2005-12-21 | 2007-07-05 | Wyeth | Protein formulations with reduced viscosity and uses thereof |
TW200804593A (en) * | 2006-01-24 | 2008-01-16 | Domantis Ltd | Fusion proteins that contain natural junctions |
AU2007227292B2 (en) * | 2006-03-17 | 2012-04-12 | Biogen Ma Inc. | Stabilized polypeptide compositions |
EP2006381B1 (en) * | 2006-03-31 | 2016-02-03 | Chugai Seiyaku Kabushiki Kaisha | Method for controlling blood pharmacokinetics of antibodies |
EP4218801A3 (en) | 2006-03-31 | 2023-08-23 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
JP2010514409A (ja) * | 2006-06-21 | 2010-05-06 | アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | ヒトの癌における鑑別式サイトカイン発現 |
WO2008003514A2 (en) * | 2006-07-06 | 2008-01-10 | Apogenix Gmbh | Human il-4 muteins in combination with chemotherapeutics or pro-apoptotic agents in cancer therapy |
AU2007292253A1 (en) * | 2006-09-08 | 2008-03-13 | Wyeth | Arginine wash in protein purification using affinity chromatography |
AU2007351514B2 (en) | 2006-09-08 | 2013-02-21 | Abbvie Inc. | Interleukin -13 binding proteins |
US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
BRPI0719250A2 (pt) * | 2006-10-12 | 2015-06-16 | Wyeth Corp | Métodos e composições com opalescência reduzida. |
EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
WO2008057240A2 (en) | 2006-10-27 | 2008-05-15 | Abbott Biotechnology Ltd. | Crystalline anti-htnfalpha antibodies |
MX2009005725A (es) * | 2006-12-11 | 2009-08-24 | Wyeth Corp | Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13. |
CA2674608A1 (en) * | 2007-01-09 | 2008-07-17 | Wyeth | Anti-il-13 antibody formulations and uses thereof |
CA2675233A1 (en) | 2007-01-16 | 2008-07-24 | Abbott Laboratories | Methods for treating psoriasis |
MX2009009080A (es) * | 2007-02-23 | 2009-11-02 | Schering Corp | Anticuerpos anti-interleucina-23p19 manipulados por ingenieria genetica. |
DK2426144T3 (en) | 2007-02-23 | 2019-01-07 | Merck Sharp & Dohme | Manipulated Anti-IL-23P19 Antibodies |
EP2527364A1 (en) * | 2007-03-29 | 2012-11-28 | Abbott Laboratories | Crystalline anti-human IL-12 antibodies |
RU2009140134A (ru) * | 2007-04-23 | 2011-05-27 | Вайет (Us) | Способы и композиции для лечения и мониторинга лечения связанных с ил-13 нарушений |
US7890055B1 (en) * | 2007-07-09 | 2011-02-15 | Everlokt Corporation | Touch field compound field detector personal ID |
RU2010107994A (ru) | 2007-08-08 | 2011-09-20 | Эбботт Лэборетриз (Us) | Композиции и способы кристаллизации антител |
SG193868A1 (en) | 2007-09-26 | 2013-10-30 | Chugai Pharmaceutical Co Ltd | Modified antibody constant region |
PL2202245T3 (pl) | 2007-09-26 | 2017-02-28 | Chugai Seiyaku Kabushiki Kaisha | Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
JP2009106163A (ja) * | 2007-10-26 | 2009-05-21 | Kyushu Univ | 核酸配列、ベクター、形質転換体、製造方法、及び、核酸配列プライマー |
US20090148905A1 (en) * | 2007-11-30 | 2009-06-11 | Claire Ashman | Antigen-binding constructs |
ES2834741T3 (es) | 2007-12-05 | 2021-06-18 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-NR10 y uso del mismo |
CN102037011A (zh) | 2008-03-18 | 2011-04-27 | 雅培制药有限公司 | 用于治疗银屑病的方法 |
CA2728909A1 (en) | 2008-07-08 | 2010-01-14 | Abbott Laboratories | Prostaglandin e2 binding proteins and uses thereof |
US8399630B2 (en) | 2008-08-20 | 2013-03-19 | Centocor Ortho Biotech Inc. | Engineered anti-IL-13 antibodies, compositions, methods and uses |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
WO2010054212A1 (en) * | 2008-11-06 | 2010-05-14 | Alexion Pharmaceuticals, Inc. | Engineered antibodies with reduced immunogenicity and methods of making |
GB0904214D0 (en) * | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
EP2826789A1 (en) | 2009-03-19 | 2015-01-21 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
JP5717624B2 (ja) | 2009-03-19 | 2015-05-13 | 中外製薬株式会社 | 抗体定常領域改変体 |
WO2010131733A1 (ja) | 2009-05-15 | 2010-11-18 | 中外製薬株式会社 | 抗axl抗体 |
US20120177668A1 (en) * | 2009-07-06 | 2012-07-12 | The Australian National University | Immunomodulating compositions comprising interleukin 13 inhibitors and uses therefor |
WO2011037158A1 (ja) | 2009-09-24 | 2011-03-31 | 中外製薬株式会社 | 抗体定常領域改変体 |
MX2012004711A (es) * | 2009-10-20 | 2012-05-23 | Abbott Lab | Aislamiento y purificacion de los anticuerpos anti-il-13 al usar cromatografia de afinidad con proteina a. |
WO2011108714A1 (ja) | 2010-03-04 | 2011-09-09 | 中外製薬株式会社 | 抗体定常領域改変体 |
WO2011133886A2 (en) | 2010-04-23 | 2011-10-27 | Genentech, Inc. | Production of heteromultimeric proteins |
MY166429A (en) | 2010-11-17 | 2018-06-26 | Chugai Pharmaceutical Co Ltd | Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii |
EP3447491A3 (en) | 2010-12-16 | 2019-06-05 | F. Hoffmann-La Roche AG | Diagnosis and treatments relating to th2 inhibition |
CA2825064C (en) | 2011-02-04 | 2022-08-30 | Genentech, Inc. | Fc variants and methods for their production |
US10689447B2 (en) | 2011-02-04 | 2020-06-23 | Genentech, Inc. | Fc variants and methods for their production |
SG10201609665PA (en) | 2011-02-25 | 2017-01-27 | Chugai Pharmaceutical Co Ltd | FcɣRIIb-SPECIFIC Fc ANTIBODY |
TWI700093B (zh) | 2011-03-16 | 2020-08-01 | 法商賽諾菲公司 | 雙重v區類抗體蛋白質之用途 |
KR20140061403A (ko) | 2011-07-13 | 2014-05-21 | 애브비 인코포레이티드 | 항―il―13 항체를 이용하여 천식을 치료하기 위한 방법 및 조성물 |
US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
TW201817744A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之FcRn結合域的治療性抗原結合分子 |
WO2014004436A2 (en) | 2012-06-27 | 2014-01-03 | Merck Sharp & Dohme Corp. | Crystalline anti-human il-23 antibodies |
KR101521224B1 (ko) * | 2012-12-20 | 2015-05-19 | 한양대학교 산학협력단 | T 세포 특이적인 인간화 단일조각항체 전달체 |
DK2948134T3 (da) | 2013-01-24 | 2020-06-02 | Palvella Therapeutics Inc | Sammensætninger til transdermal indgivelse af mtor-inhibitorer |
AR095774A1 (es) * | 2013-04-05 | 2015-11-11 | Genentech Inc | Anticuerpos anti-il-4 y anticuerpos biespecíficos y sus usos |
NZ718144A (en) | 2013-09-13 | 2022-05-27 | Genentech Inc | Methods and compositions comprising purified recombinant polypeptides |
BR112016004437A2 (pt) | 2013-09-13 | 2017-10-17 | Genentech Inc | métodos de imunoteste e de seleção de linhagem de células, anticorpos e kit |
JP6534615B2 (ja) | 2013-09-27 | 2019-06-26 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
KR20160068802A (ko) | 2013-10-23 | 2016-06-15 | 제넨테크, 인크. | 호산구성 장애를 진단 및 치료하는 방법 |
CR20160379A (es) | 2014-02-21 | 2016-10-07 | Genentech Inc | Anticuerpos biespecificos anti-il 13/il-17 y sus usos |
CA2943707A1 (en) | 2014-05-06 | 2015-11-12 | Genentech, Inc. | Production of heteromultimeric proteins using mammalian cells |
MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
SG11201700841QA (en) | 2014-12-19 | 2017-03-30 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
KR20230044338A (ko) | 2014-12-19 | 2023-04-03 | 추가이 세이야쿠 가부시키가이샤 | 항-c5 항체 및 그의 사용 방법 |
CN107108729A (zh) | 2015-02-05 | 2017-08-29 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il‑8‑结合抗体,及其应用 |
AU2016224409B2 (en) | 2015-02-27 | 2021-01-28 | Chugai Seiyaku Kabushiki Kaisha | Composition for treating IL-6-related diseases |
AR103726A1 (es) | 2015-02-27 | 2017-05-31 | Merck Sharp & Dohme | Cristales de anticuerpos monoclonales anti-pd-1 humanos |
WO2016149276A1 (en) | 2015-03-16 | 2016-09-22 | Genentech, Inc. | Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases |
US11142587B2 (en) | 2015-04-01 | 2021-10-12 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide hetero-oligomer |
JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
EP3398965A4 (en) | 2015-12-28 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR PROMOTING THE EFFICACY OF PURIFYING A POLYPEPTIDE CONTAINING AN FC REGION |
MX2018010988A (es) | 2016-03-14 | 2019-01-21 | Chugai Pharmaceutical Co Ltd | Farmaco terapeutico que induce lesion celular para usarse en terapia de cancer. |
KR102460040B1 (ko) | 2016-04-27 | 2022-11-01 | 애브비 인코포레이티드 | 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법 |
CA3026050A1 (en) | 2016-08-05 | 2018-02-08 | Chugai Seiyaku Kabushiki Kaisha | Composition for prophylaxis or treatment of il-8 related diseases |
KR102557643B1 (ko) | 2016-09-23 | 2023-07-20 | 제넨테크, 인크. | 아토피성 피부염을 치료하기 위한 il-13 길항제의 용도 |
WO2018098370A1 (en) | 2016-11-23 | 2018-05-31 | Immunoah Therapeutics, Inc. | 4-1bb binding proteins and uses thereof |
AU2017370942A1 (en) | 2016-12-07 | 2019-06-13 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
IL267869B2 (en) | 2017-01-06 | 2023-10-01 | Palvella Therapeutics Inc | Non-aqueous preparations of mTOR inhibitors and methods of use |
US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
WO2018183932A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
EP3620531A4 (en) | 2017-05-02 | 2021-03-17 | National Center of Neurology and Psychiatry | METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS |
RU2019138507A (ru) | 2017-05-02 | 2021-06-02 | Мерк Шарп И Доум Корп. | Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1 |
CN109776677B (zh) * | 2017-11-15 | 2023-11-03 | 尚华科创投资管理(江苏)有限公司 | 一种人源化抗il-13抗体及其制备方法和应用 |
KR20230142806A (ko) | 2018-02-09 | 2023-10-11 | 제넨테크, 인크. | 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법 |
GB201802487D0 (en) | 2018-02-15 | 2018-04-04 | Argenx Bvba | Cytokine combination therapy |
MA52011A (fr) | 2018-03-16 | 2021-01-20 | Zoetis Services Llc | Vaccins peptidiques contre l'interleukine-31 |
CA3093539A1 (en) | 2018-03-16 | 2019-09-19 | Zoetis Services Llc | Interleukin-31 monoclonal antibodies for veterinary use |
US11000513B2 (en) | 2018-07-02 | 2021-05-11 | Palvella Therapeutics, Inc. | Anhydrous compositions of mTOR inhibitors and methods of use |
WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
KR20210095165A (ko) | 2018-11-19 | 2021-07-30 | 프로제너티, 인크. | 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스 |
EP3941589A1 (en) | 2019-03-21 | 2022-01-26 | Regeneron Pharmaceuticals, Inc. | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
CN113677708A (zh) * | 2019-03-26 | 2021-11-19 | 亚狮康私人有限公司 | 采用抗il13r抗体或其结合片段的治疗 |
EP4309722A2 (en) | 2019-12-13 | 2024-01-24 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
CN114605535A (zh) * | 2020-12-08 | 2022-06-10 | 深圳福沃药业有限公司 | 抗il-13抗体及其用途 |
BR112023017490A2 (pt) | 2021-03-17 | 2023-11-07 | Receptos Llc | Métodos de tratamento de dermatite atópica com anticorpos anti il-13 |
CN118076636A (zh) | 2021-09-15 | 2024-05-24 | 德米拉公司 | Il-13抑制剂用于治疗结节性痒疹 |
CA3235096A1 (en) | 2021-11-17 | 2023-05-25 | Disc Medicine, Inc. | Methods for treating anemia of kidney disease |
Family Cites Families (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
DE3883899T3 (de) * | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
WO1989004838A1 (en) | 1987-11-25 | 1989-06-01 | Immunex Corporation | Interleukin-1 receptors |
US5359037A (en) | 1988-09-12 | 1994-10-25 | Yeda Research And Development Co. Ltd. | Antibodies to TNF binding protein I |
WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5011778A (en) | 1989-05-23 | 1991-04-30 | Otsuka Pharmaceutical Co., Ltd. | Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies |
ZA9010190B (en) | 1989-12-20 | 1991-08-28 | Schering Corp | Antibody antagonists of human interleukin-4 |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5246701A (en) | 1990-10-05 | 1993-09-21 | Ludwig Institute For Cancer Research | Method for inhibiting production of IgE by using IL-9 inhibitors |
MD1652G2 (ro) | 1991-03-29 | 2001-12-31 | Sanofi-Synthelabo | Proteină cu activitate de tip citochină, ADN recombinant, codificator pentru această proteină, celule şi microorganisme transformate, vector de expresie, procedeu de obţinere a proteinei şi remediu care conţine această proteină |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
WO1993015766A1 (en) | 1992-02-10 | 1993-08-19 | Seragen, Inc. | Desensitization to specific allergens |
US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
WO1994004680A1 (en) | 1992-08-21 | 1994-03-03 | Schering Corporation | Human interleukin-13 |
US5596072A (en) * | 1992-08-21 | 1997-01-21 | Schering Corporation | Method of refolding human IL-13 |
EP0604693A1 (en) | 1992-12-29 | 1994-07-06 | Schering-Plough | Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same |
EP0721469B1 (en) | 1993-09-02 | 2000-01-05 | Trustees of Dartmouth College | Anti-gp39 antibodies and uses therefor |
US5928904A (en) | 1993-09-07 | 1999-07-27 | Smithkline Beecham Corporation | DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
EP0659766A1 (en) | 1993-11-23 | 1995-06-28 | Schering-Plough | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
GB9415379D0 (en) | 1994-07-29 | 1994-09-21 | Smithkline Beecham Plc | Novel compounds |
NZ292124A (en) | 1994-07-29 | 1998-10-28 | Smithkline Beecham Plc | Il-4 antagonist comprising a fusion of a mutant il-4-antibody fragment |
US5696234A (en) | 1994-08-01 | 1997-12-09 | Schering Corporation | Muteins of mammalian cytokine interleukin-13 |
US5705154A (en) | 1995-03-08 | 1998-01-06 | Schering Corporation | Humanized monoclonal antibodies against human interleukin-4 |
US20010053371A1 (en) | 1999-01-07 | 2001-12-20 | Waldemar Debinski | Method for diagnosing, imaging, and treating tumors using restrictive receptor for interleukin 13 |
CA2238080C (en) | 1995-10-23 | 2012-03-13 | Amrad Operations Pty. Ltd. | A novel haemopoietin receptor and genetic sequences encoding same |
US6911530B1 (en) | 1995-10-23 | 2005-06-28 | Amrad Operations, Pty., Ltd. | Haemopoietin receptor and genetic sequences encoding same |
FR2742156A1 (fr) | 1995-12-06 | 1997-06-13 | Sanofi Sa | Polypeptide recepteur de l'il-13 |
CA2243459C (en) | 1996-02-09 | 2002-09-17 | Basf Aktiengesellschaft | Human antibodies that bind human tnf.alpha. |
US6664227B1 (en) | 1996-03-01 | 2003-12-16 | Genetics Institute, Llc | Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains |
US5710023A (en) | 1996-03-01 | 1998-01-20 | Genetics Institute, Inc. | IL-13 cytokine receptor chain |
US7078494B1 (en) | 1996-03-01 | 2006-07-18 | Genetics Institute, Llc | Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding |
WO1997033913A1 (en) | 1996-03-13 | 1997-09-18 | Zymogenetics, Inc. | Cytokine-receptor expressed in testis cells |
EP0812913A3 (en) | 1996-06-12 | 1999-08-04 | Smithkline Beecham Corporation | HR-1 receptor, a receptor of the cytokine receptors family |
AU6175696A (en) | 1996-06-12 | 1998-01-07 | Human Genome Sciences, Inc. | Hr-1 receptor |
WO1997047742A1 (en) | 1996-06-12 | 1997-12-18 | Smithkline Beecham Corporation | Hr-1 receptor |
WO1998010638A1 (en) | 1996-09-10 | 1998-03-19 | Amrad Operations Pty. Ltd. | Therapeutic molecules |
GB9625899D0 (en) | 1996-12-13 | 1997-01-29 | Glaxo Group Ltd | Substances and their uses |
BR9714523A (pt) | 1997-01-10 | 2000-05-02 | Biogen Inc | Tratamento de nefrite de lúpus com compostos anti-cd40l |
US6387615B2 (en) | 1997-04-11 | 2002-05-14 | Isis Innovation Limited | Methods and materials for the diagnosis or prognosis of asthma |
GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
GB9723553D0 (en) | 1997-11-07 | 1998-01-07 | Duff Gordon W | Prediction of the risk of chronic obstructive airway disease |
JP4460155B2 (ja) | 1997-12-05 | 2010-05-12 | ザ・スクリプス・リサーチ・インステイチユート | マウス抗体のヒト化 |
US6746839B1 (en) * | 1998-01-12 | 2004-06-08 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for an obstructive airway disease |
US6576232B1 (en) | 1998-04-03 | 2003-06-10 | The Penn State Research Foundation | IL13 mutants |
US7083950B2 (en) | 1998-09-25 | 2006-08-01 | Regeneron Pharmaceuticals, Inc. | High affinity fusion proteins and therapeutic and diagnostic methods for use |
PT1141286E (pt) | 1998-12-14 | 2007-01-31 | Genetics Inst Llc | Cadeia de receptores de citocina |
US7553487B2 (en) | 1998-12-14 | 2009-06-30 | Genetics Institute, Llc | Method and compositions for treating asthma |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
MXPA01008142A (es) | 1999-02-10 | 2003-07-21 | Welfide Corp | Compuestos de amida, y uso medicinal de los mismos. |
AU5756100A (en) | 1999-06-21 | 2001-01-09 | Genetics Institute Inc. | Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains |
AU2000278349A1 (en) | 1999-09-28 | 2001-04-30 | Genaissance Pharmaceuticals, Inc. | Drug target isogenes: polymorphisms in the interleukin 13 gene |
EP1222212A4 (en) | 1999-10-06 | 2005-05-04 | Penn State Res Found | MUTANTS OF IL-13 |
GB0004016D0 (en) | 2000-02-22 | 2000-04-12 | Royal Brompton Hospital | Biological material and uses thereof |
US6846486B1 (en) | 2000-02-24 | 2005-01-25 | Advanced Biotherapy Concepts, Inc. | Method of treating allergy by administering an anti-histamine antibody |
WO2001077332A2 (en) | 2000-04-07 | 2001-10-18 | Heska Corporation | Compositions and methods related to canine igg and canine il-13 receptors |
EP3190126A1 (en) | 2000-05-26 | 2017-07-12 | Immunex Corporation | Use of interleukin-4 receptor (il-4r) antibodies and compositions thereof |
AU8867501A (en) | 2000-09-01 | 2002-03-13 | Biogen Inc | Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
WO2002055100A2 (en) | 2000-10-20 | 2002-07-18 | Genetics Institute, Llc | Method and composition for inhibition of tumor growth and enhancing an immune response |
IL156618A0 (en) * | 2000-12-28 | 2004-01-04 | Altus Biologics Inc | Crystals of whole antibodies and fragments thereof, methods for the preparation thereof and diagnostic kits utilizing the same |
US6649935B2 (en) | 2001-02-28 | 2003-11-18 | International Business Machines Corporation | Self-aligned, planarized thin-film transistors, devices employing the same |
GB0105360D0 (en) | 2001-03-03 | 2001-04-18 | Glaxo Group Ltd | Chimaeric immunogens |
US7216242B2 (en) * | 2001-03-16 | 2007-05-08 | Dualcor Technologies, Inc. | Personal electronics device with appliance drive features |
AUPR544401A0 (en) * | 2001-06-04 | 2001-06-28 | Bischof, Robert Juergen | Animal model for allergy |
EP1402451A4 (en) | 2001-06-07 | 2005-01-05 | Wyeth Corp | SOLUTION STRUCTURE OF IL-13 AND USE THEREOF |
US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
US20030023555A1 (en) | 2001-07-26 | 2003-01-30 | Cashworks, Inc. | Method and system for providing financial services |
CA2842429A1 (en) | 2001-10-19 | 2003-05-01 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders |
US20040234499A1 (en) | 2001-10-26 | 2004-11-25 | David Shealy | Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses |
WO2003035847A2 (en) * | 2001-10-26 | 2003-05-01 | Centocor, Inc. | Il-13 mutein proteins, antibodies, compositions, methods and uses |
US20040248260A1 (en) | 2001-10-26 | 2004-12-09 | Heavner George A. | IL-13 mutein proteins, antibodies, compositions, methods and uses |
US20050154192A1 (en) | 2001-11-27 | 2005-07-14 | Kamon Shirakawa | Anti-il13 receptor alpha1 neutralizing antibody |
EP1455833A1 (en) | 2001-12-04 | 2004-09-15 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES | Chimeric molecule for the treatment of th2-like cytokine mediated disorders |
EP1325868A1 (en) | 2002-01-08 | 2003-07-09 | Tetra Laval Holdings & Finance SA | Packaging unit for continuously producing sealed packages, containing pourable food products, from a tube of packaging material |
JP4432031B2 (ja) | 2002-03-22 | 2010-03-17 | ズィナイス オペレーションズ ピーティーワイ.エルティーディー. | インターロイキン13受容体α1(IL−13Rα1)に対するモノクローナル抗体 |
WO2003086451A1 (en) * | 2002-04-05 | 2003-10-23 | Centocor, Inc. | Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses |
WO2003092610A2 (en) | 2002-05-01 | 2003-11-13 | Regeneron Pharmaceuticals, Inc. | Methods of using cytokine antagonists to treat hiv infection and aids |
EP1552462B1 (en) | 2002-06-14 | 2011-03-23 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Methods of treating and preventing colitis involving il-13 and nk-t cells |
JP2004121218A (ja) * | 2002-08-06 | 2004-04-22 | Jenokkusu Soyaku Kenkyusho:Kk | 気管支喘息または慢性閉塞性肺疾患の検査方法 |
US20060104943A1 (en) * | 2002-08-30 | 2006-05-18 | Claire Ashman | Vaccine comprising il-13 and an adjuvant |
EP1576137A4 (en) | 2002-10-29 | 2010-06-30 | Genentech Inc | COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM |
US20070048301A1 (en) | 2002-11-26 | 2007-03-01 | Bodary-Winter Sarah C | Compositions and methods for the treatment of immune related diseases |
CA2508375C (en) | 2002-12-02 | 2014-05-27 | Abgenix, Inc. | Antibodies directed to tumor necrosis factor and uses thereof |
EP1444989A1 (en) | 2003-02-07 | 2004-08-11 | Giorgio Dr. Stassi | Sensitizing cells for apoptosis by selectively blocking cytokines |
GB0407315D0 (en) * | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
EP1651266B1 (en) | 2003-07-25 | 2010-03-03 | Laboratorios Silanes, S.A. de C.V. | Administration of anti-tnf-alpha f(ab')2 antibody fragments |
WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
WO2005042028A2 (en) | 2003-10-27 | 2005-05-12 | Neopharm, Inc. | Il-13 conjugated to an immunogen and uses thereof |
PT1703893E (pt) | 2003-12-23 | 2012-06-01 | Genentech Inc | Novos anticorpos anti-il 13 e as respectivas utilizações |
JP2007525210A (ja) * | 2003-12-24 | 2007-09-06 | ワイス | 喘息の処置方法 |
EP1713441A2 (en) | 2004-02-12 | 2006-10-25 | Nektar Therapeutics | Interleukin-13 antagonist powders, spray-dried particles, and methods |
CA2557724A1 (en) | 2004-02-27 | 2005-10-06 | Centocor, Inc. | Methods and compositions for treating il-13 related pathologies |
US20090098142A1 (en) | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
US20070048785A1 (en) | 2004-06-09 | 2007-03-01 | Lin Laura L | Anti-IL-13 antibodies and complexes |
AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
MX2009005725A (es) | 2006-12-11 | 2009-08-24 | Wyeth Corp | Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13. |
RU2009140134A (ru) | 2007-04-23 | 2011-05-27 | Вайет (Us) | Способы и композиции для лечения и мониторинга лечения связанных с ил-13 нарушений |
-
2005
- 2005-06-08 AR ARP050102343A patent/AR049390A1/es active IP Right Grant
- 2005-06-09 JP JP2007527730A patent/JP2008515776A/ja not_active Withdrawn
- 2005-06-09 EP EP05786816A patent/EP1756161A2/en not_active Withdrawn
- 2005-06-09 KR KR1020137008282A patent/KR101462878B1/ko not_active IP Right Cessation
- 2005-06-09 US US11/149,309 patent/US7615213B2/en not_active Expired - Fee Related
- 2005-06-09 BR BRPI0510881-0A patent/BRPI0510881A/pt not_active IP Right Cessation
- 2005-06-09 SG SG200706331-6A patent/SG135207A1/en unknown
- 2005-06-09 EP EP05786668A patent/EP1765401A4/en not_active Withdrawn
- 2005-06-09 MX MXPA06014298A patent/MXPA06014298A/es unknown
- 2005-06-09 JP JP2007527694A patent/JP4970258B2/ja not_active Expired - Fee Related
- 2005-06-09 NZ NZ582046A patent/NZ582046A/en not_active IP Right Cessation
- 2005-06-09 RU RU2006140793/10A patent/RU2427589C2/ru not_active IP Right Cessation
- 2005-06-09 AU AU2005253981A patent/AU2005253981B2/en not_active Ceased
- 2005-06-09 WO PCT/US2005/020160 patent/WO2005123126A2/en active Application Filing
- 2005-06-09 RU RU2006140096/13A patent/RU2006140096A/ru not_active Application Discontinuation
- 2005-06-09 SG SG200905834-8A patent/SG155260A1/en unknown
- 2005-06-09 KR KR1020067025945A patent/KR20070034487A/ko not_active Application Discontinuation
- 2005-06-09 CA CA002567129A patent/CA2567129A1/en not_active Abandoned
- 2005-06-09 MX MXPA06014299A patent/MXPA06014299A/es active IP Right Grant
- 2005-06-09 WO PCT/US2005/020334 patent/WO2005121177A2/en active Application Filing
- 2005-06-09 KR KR1020067025990A patent/KR101299073B1/ko not_active IP Right Cessation
- 2005-06-09 CN CN2005800191385A patent/CN101141980B/zh not_active Expired - Fee Related
- 2005-06-09 BR BRPI0511910-3A patent/BRPI0511910A/pt not_active IP Right Cessation
- 2005-06-09 TW TW094119110A patent/TWI391133B/zh active
- 2005-06-09 CA CA002567081A patent/CA2567081A1/en not_active Abandoned
- 2005-06-09 EP EP12169663A patent/EP2548889A1/en not_active Withdrawn
- 2005-06-09 AU AU2005252700A patent/AU2005252700A1/en not_active Withdrawn
- 2005-06-09 CN CN2012102800731A patent/CN102827280A/zh active Pending
-
2006
- 2006-11-07 IL IL179093A patent/IL179093A0/en unknown
- 2006-11-22 IL IL179476A patent/IL179476A/en not_active IP Right Cessation
- 2006-12-05 CR CR8784A patent/CR8784A/es not_active Application Discontinuation
- 2006-12-05 CR CR8783A patent/CR8783A/es not_active Application Discontinuation
- 2006-12-11 EC EC2006007072A patent/ECSP067072A/es unknown
- 2006-12-11 EC EC2006007073A patent/ECSP067073A/es unknown
-
2007
- 2007-01-05 NO NO20070087A patent/NO20070087L/no not_active Application Discontinuation
- 2007-01-08 NO NO20070133A patent/NO20070133L/no unknown
-
2009
- 2009-10-08 US US12/575,896 patent/US8221752B2/en not_active Expired - Fee Related
-
2010
- 2010-08-17 AR ARP100103010A patent/AR077931A2/es unknown
-
2011
- 2011-03-09 JP JP2011051866A patent/JP2011155980A/ja active Pending
-
2014
- 2014-08-20 JP JP2014167064A patent/JP2015037401A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR8783A (es) | Anticuerpos anti-il13 y complejos | |
DE60329489D1 (de) | Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon | |
BRPI0314814C1 (pt) | anticorpo compreendendo uma variante de fc | |
CY1117124T1 (el) | ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ANTΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ | |
DK1773885T3 (da) | Humaniserede anti-c-met-antagonister | |
NO20071436L (no) | Humaniserte Anti-5T4 antistoffer og Anti-5T4 antistoff/calicheamicin konjugater | |
EA200870130A1 (ru) | Антитела против ил-6, предотвращающие связывание с gp130 комплекса ил-6 и альфа-рецептора ил-6 | |
AR057807A1 (es) | Formulaciones de anticuerpo anti-cd3 | |
DK1766093T3 (da) | Antistoffer mod clostridium difficile-toksiner og anvendelse deraf | |
GEP20115226B (en) | P-cadherin antibodies | |
TW200732350A (en) | Methods for generating monovalent IgG | |
CY1110843T1 (el) | Αντισωματα εναντι il-22ra και εταιροι δεσμευσης και μεθοδοι χρησης σε φλεγμονη | |
NZ588674A (en) | Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof | |
DK2316852T3 (da) | Stabiliserede enkeltdomæne-antistoffer | |
ATE475673T1 (de) | Anti-il-22ra antikörper und bindungspartner und verwendungsmethoden bei entzündung | |
NO20083891L (no) | Anti-5T4 antistoffer og anvendelser derav | |
EA200700917A1 (ru) | Способ рефолдинга рекомбинантных антител | |
NO20083127L (no) | Fremgangsmater og preparater for malretting av polyubiquitin | |
HK1074670A1 (en) | Sets of digital antibodies directed against short epitopes, and methods using same | |
DE60325892D1 (de) | Stellungs- und verwendungsverfahren | |
WO2003078468A3 (de) | Verwendung einer an cd28 bindenden wirksubstanz zur herstellung einer pharmazeutischen zusammensetzung | |
ATE497392T1 (de) | Therapie mit anti-cd4-antikörpern und bestrahlung | |
DK1519748T3 (da) | Mikropartikler med CD28-specifikke monoklonale antistoffer | |
NO20090333L (no) | Fremgangsmater og preparater rettet mot hepsin | |
NO20083609L (no) | Fremgangsmater og sammensetninger for malrettet-RELT |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |